Cipla reported robust performance in Q3 FY26, driven by strong double-digit growth in its India business. Revenue reached INR 7,074 Cr, with EBITDA at INR 1,255 Cr (18% of revenue) and PAT at INR 676 Cr (10% of revenue). The company saw notable success in its One India segment, North America, One Africa, and Emerging Markets & Europe businesses.
India Business Performance
Cipla’s India business demonstrated strong growth, with revenue reaching INR 3,457 Cr. Respiratory products significantly outperformed the Indian Pharmaceutical Market (IPM) growth by over 400 bps.
North America Overview
The North America business reported revenue of $167 Mn. Albuterol maintained its leading position, ranking #1 in the overall U.S. Albuterol MDI market with a market share of 22%.
One Africa and Emerging Markets
The One Africa business generated $112 Mn in revenue, ranking #2 in the South African prescription market. The Emerging Markets & Europe segment achieved $104 Mn in revenue, marking its fourth consecutive quarter exceeding $100 Mn.
Key Financial Metrics for Q3 FY26
Key consolidated financial figures for the quarter include:
- Revenue: INR 7,074 Cr
- EBITDA: INR 1,255 Cr (17.7% EBITDA margin)
- PAT: INR 676 Cr (9.6% PAT margin)
- R&D Spend: INR 494 Cr (7.0% of revenue)
- Cash Balance: INR 10,718 Cr
- Net Cash: INR 10,229 Cr
One India Strategy and Alliances
Cipla strategically partnered with Pfizer to market and distribute key Pfizer brands in India. The company also acquired Inzpera Healthsciences to expand its pediatric and wellness portfolio.
Consumer Wellness Franchise Performance
The Consumer Brands in One India generated revenue of INR 442 Cr. The Consumer Brands in South Africa generated revenue of ZAR 354 Mn.
ANDA Pipeline Update
As of December 31, 2025, Cipla’s ANDA pipeline included 179 approved ANDAs & NDAs, 49 tentatively approved ANDAs & NDAs, and 54 under approval ANDAs & NDAs, totaling 282.
Source: BSE
